<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-2-02-12-2025-shutterstock_1243951654-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-2-02-12-2025-shutterstock_1243951654-430x241.jpg"/>
                                    
                                    <figcaption>The therapy aims to restore therapeutic frataxin protein levels to address cardiac, neurological and systemic symptoms of FA. Credit: Gorodenkoff/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<figure class="wp-block-image size-large"></figure>



<p>Solid Biosciences has secured the US Food and Drug Administration (FDA) rare paediatric disease designation for SGT-212, its investigational gene therapy targeting Friedreich’s ataxia (FA).</p>



<p>The designation, which covers serious and life-threatening diseases affecting those under 18, may allow the company a paediatric priority review voucher for future regulatory submissions.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - AB-1005 in Multiple System Atrophy (MSA or Shy... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - LYSSAF-302 in Mucopolysaccharidosis III (MPS I... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>SGT-212 is designed to deliver the full-length human frataxin gene through a dual-administration route, combining direct intradentate nucleus (IDN) and intravenous (IV) infusions.</p>



<p>The frataxin gene will be delivered into the intradentate nucleus using a stereotactic, magnetic resonance imaging-guided device approved by the FDA.</p>



<p>The therapy aims to restore therapeutic frataxin protein levels to address FA’s cardiac, neurological and systemic symptoms.</p>



<p>SGT-212 is a recombinant adeno-associated virus (AAV)-based gene replacement therapy for FA.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Solid Biosciences chief regulatory and preclinical operations officer Jessie Hanrahan stated: “Receiving paediatric rare disease designation marks another significant milestone for our Friedreich’s ataxia programme, SGT-212.</p>



<p>“Together with the fast track designation granted earlier this year, it recognises our dual-route clinical approach for FALCON, our first-in-human trial, which is now screening participants, as an important first step in meeting an unmet need for FA.</p>



<p>“These designations are designed to help accelerate time to market and enhance engagement with the FDA. We look forward to continued collaboration with regulators to bring this therapy to patients as quickly as possible.”</p>



<p>FA, a life-threatening, degenerative multisystem condition, results in progressive damage of the nervous system, then cardiac dysfunction and movement problems.</p>



<p>In January 2023, Solid Biosciences entered a strategic research collaboration with Phlox Therapeutics to expedite the development of new therapies for rare cardiac diseases.</p>



<p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>



<p><em>Editorial content is independently produced and follows the </em>highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>

      
    <div> 
  
        <div id="whitepaper_form">
           
  
            <div>
               
            
                <h4>Free eBook</h4><h3>Navigating cell therapy process development</h3> 
                
                    <div id="vms_description">The cell therapy manufacturing sector is rapidly evolving, driven by the need to balance innovative process development with rigorous GMP standards. This eBook, brought to you by industry leaders Cytiva, explores how biotech firms can address common challenges — including minimizing contamination risks from manual processes, overcoming resource limitations, and creating scalable, robust designs. Industry experts discuss strategies including automation, strategic outsourcing, and flexible equipment selection to streamline processes and reduce regulatory risks. To unlock expert insights on optimizing your cell therapy pathway from clinical development to commercialization, fill in your details now.</div><div id="enquiry3_2">
                   <b>Thank you.</b><p>You will receive an email shortly. Please check your inbox to download the eBook.</p> </div>  
                    <span>By Cytiva Thematic</span>    
           
                </div>
                   




            
                        <div><figure class="report-cover"><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/03/Navigating-cell-therapy-process-development-pdf.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="3413" height="1920" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/03/Navigating-cell-therapy-process-development-pdf.jpg"/>
                        </figure></div>
                        






                    </div>
                    
        
        
        
        <p>You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.</p>

            </div>
            
            
            <p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

SLDB

<p>Solid Biosciences' SGT-212 has received FDA rare paediatric disease designation, potentially allowing a priority review voucher for future submissions. SGT-212 aims to treat Friedreich’s ataxia by delivering the frataxin gene through dual administration routes. This milestone, along with a fast track designation, accelerates market entry and enhances FDA engagement. The therapy addresses FA's cardiac, neurological, and systemic symptoms, marking progress in meeting unmet needs for this degenerative condition.</p>

Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status